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Abstract 
Objective:  activation of hedgehog (Hh) pathway has
been implicated in the development of human malig-
nancies. Hh as well as related downstream target genes
has been extensively studied in many kinds of malig-
nant tumours for clinical diagnostic or prognostic util-
ities.  this  study  aimed  at  investigating  whether  Hh
molecules provides a molecular marker of hepatoblas-
toma malignancy. 
Methods: We obtained tissue sections from 32 patients
with hepatoblastoma as well as cholestasis and normal
control.  Immunohistochemical  analysis  were  per-
formed to determine Hh signal components in human
hepatoblastoma. the prognostic significance of single
expression of Hh signal components were evaluated
using Cox proportional hazards regression models and
Kaplan-Meier survival analysis for statistical analysis.
Results: Expression of Hh signal components showed
an increase in hepatoblastoma compared with chole  -
stasis and normal tissues. there was a positive correla-
tion between smo or gli1 expression and tumor clini-
copathological features, such as histological type, tu-
mor grade, tumor size and clinical stage. both smo or
gli1 protein high expression was significantly associat-
ed  with  poor  prognosis  by  univariate  analyses  and
multivariate analyses. 
Conclusions: abnormal  Hh  signaling  activation  plays
important roles in the malignant potential of hepato-
blastoma. gli1 expression is an independent prognos-
tic marker. 
Kew words: Hedgehog (Hh); Hepatoblastoma; Progno-
sis; Indicator
Abbreviations: Hh:  hedgehog;  shh:  sonic  hedgehog;
smo, smoothened; gli-1: glioma-associated oncogene
homologue 1; Ptch1: patched1.
IntRoDuCtIon
Hepatoblastoma is one of the commonly diagnosed
pediatric tumours all over the world. the prognosis of
the patients with hepatoblastoma is various. Presently,
there are few clues as to its pathogenesis and biologi-
cal characteristics [1, 2, 3]. Except for stage of disease,
there are few markers to predict the prognosis of pa-
tients or to evaluate the malignant grade of hepato-
blastoma. Elucidation of the useful prognosis-predict-
ing factors is necessary to improve the prognosis of
patients with hepatoblastoma. one area of intense re-
search  is  the  identification  of  molecular  markers  to
fully assess the prognosis of patients and to define in-
novative strategies. It has revealed that activation and
inactivation of specific molecular markers plays critical
roles in hepatoblastoma and other malignant diseases
[4, 5]. this plays an important role in the pathogenesis
of hepatoblastoma, but is not considered to be a good
molecular  marker  to  distinguish  high-risk  tumours
from others [6, 7]. Expanded use of these markers for
the diagnosis and individualization of therapy, howev-
er, has been hampered by a lack of universal accep-
tance of their pro  gnostic significance. there is still no
consensus in clinical practice on how to evaluate the
effectiveness of candidate molecular markers in evalu-
ating its prognostics. 
Recently, a series of studies reported that the Hh
signaling  pathway  is  involved  in  differentiation  and
progression of a variety of malignant processes, in-
cluding  both  solid  tumors  and  hematopoietic  neo-
plasms [8, 9, 10]. Hedgehog (Hh) pathway is a system
that is known to regulate the viability and differentia-
tion of various types of progenitors. Hh ligands are
soluble, lipid-modified morphogens that interact with
patched (Ptc), a membrane-spanning receptor on the
surface of Hh responsive cells. this ligand-receptor
interaction prevents Ptc from inhibiting its coreceptor,
smoothened (smo), a member of the seven transmem-
brane-receptor family. activated smo, in turn, initiates
a series of intracellular events that culminate in activa-
tion  and  nuclear  localization  of  glioblastoma  (gli)
family transcription factors, which is associated with
development  of  basal  cell  carcinomas  and  medul-
loblastomas. signaling is turned off when the level of
Ptc exceeds that of Hh ligands, permitting “free” Ptc
to interact with and inhibit smo [11].
although  few  reports  have  shown  blocking  the
hedge  hog  pathway  inhibits  hepatoblastoma  growth.
there is no definitive data to accurately predict a corre-
lation between Hh pathway and the clinicopathological
features of hepatoblastoma and long-term outcome in
patients. to evaluate the role of hedgehog pathway as
factor  to  provide  a  molecular  marker  of  hepatoblas-
toma neoplastic process and biologic behavior of the
tumor. the present study,for the first time to ourknowl  -
edge, combined molecular analysis of Hh pathway in
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MatERIaLs anD MEtHoDs
PatIEnts CHaRaCtERIstICs anD tIssuE saMPLEs
Hepatoblastoma tissue samples were obtained from 32
patients who were referred to the affiliated hospital of
Chongqing Medical university, Chongqing, P. R. Chi-
na, with detailed clinical data. all subjects were ethnic
Chinese. the patients with these tumours were treated
under the framework of the guideline from Chinese
Medical  association.  the  clinical  stages  of  disease
were determined at the time of initial biopsy or resec-
tion  according  to  the  classification  of  the  Chinese
Medical association of Pediatric surgeons. Histologi-
cal subtypes were diagnosed according to the classifi-
cation of Haas et al. [12]. Control liver tissues was ob-
tained from cholestatic disease patients with compara-
ble age, including patients who had severe cholestasis,
diagnosed with choledochal cysts (CDCs) at the time
of cyst excision (n = 4). Cholestatic disease were cho-
sen because of similiarities of Hh pathway activition
reported.  normal  controls  included  5  percutaneous
liver  biopsy  under  general  anesthetic  to  rule  out
glycogen storage disease. all diagnoses were based on
clinical and laboratory data and on histopathological
examination  of  histological  samples.  this  study  was
performed according to a protocol approved by the
Institutional Review board of the Chongqing Medical
university, Chongqing, Peoples Republic of China in
accordance  with  the  ethical  standards  prescribed  by
the Helsinki Declaration of the World Medical associ-
ation.  Written  informed  consent  was  obtained  from
the parents prior to specimen collection. the patients
were followed every 3 months by clinical examination
and basic laboratory tests during the first three years
from diagnosis and then every 6 months. the median
follow-up  in  our  study  is  55  months  (range  39-60
months). survival was calculated at the time from fol-
low-up to death from any cause for overall survival.
for overall survival, all deaths, irrespective of cause,
were considered events. Data concerning the patients
who died from other causes or who were still alive at
the end of our study were censored.
IMMunoHIstoCHEMIstRY
Contiguous  4-ﾵm  formalin-fixed,  paraffin-embedded
sections were firstly submitted to rehydrate by incubat-
ing successively in 100%, 90%, and 70% ethanol. after
deparaffinizating  to  water,  heat-induced  epitope  re-
trieval was unmasked in citrate buffer with steam for
60 min. sections were then incubated overnight at 4_
with an optimal dilution (0.1 mg/L) of a primary poly-
clonal goat antibody against human shh (n-19), Ptc
(C-20), smo (n-19) and gli-1 (C-18) (1:160 dilution,
mouse  clone,  santa  Cruz  biotechnology  Inc.,  santa
Cruz, Ca). next, the tissue sections were incubated
with a 1:300 dilution of biotinylated secondary anti-
body for both proteins goat antimouse immunoglobu-
lins (shanghai sangon biotech, shanghai, China). af-
ter development of the color with diaminobenzidine,
the slides were counterstained with hematoxylin. neg-
ative control slides were run with every batch, which
included  an  isotype-matched  immunoglobulin  at  the
same concentration as that of the primary antibody.
basal cell carcinoma tissue served as the internal posi-
tive control for shh, Ptc, smo and gli-1 immunoreac-
tivity. under standard light microscopy at _400, single
neoplastic cell positive cytoplasmic and nuclear stain-
ing was defined as described previously [13]. Cytoplas-
mic- and nuclear-positive cells of average 20 fields per
tumor(100  cells  per  field)  from  typical  section  were
counted and submitted to positive rates. all Immuno-
histochemical slides were performed independently by
two  investigators  (Jin  Zhu  and  Chunping  xiang).  If
positive rate exceed 5%, immunostaining result were
consided positive for this patient. 
statIstICaL anaLYsIs
statistical  comparisons  were  carried  out  using  sPss
software for Windows (sPss, Inc., Chicago, IL). Pear-
son’s c2 test or fisher’s exact test was used to examine
correlations between the Hh signal staining percentages
and the clinicopathologic features. the overall survival
curves for each group of patients were estimated by the
Kaplan–Meier  method  and  the  resulting  curves  were
compared  using  the  Cox–Mantel  test.  univariate  and
multivariate Cox proportional hazards regression mod-
els were used to examine prognostic value of the smo
or gli1 staining, and other clinicopathologic features.
survival  curves  were  constructed  using  the  Kaplan-
Meier method and compared using the log-rank test.
the level of significance was set at p < 0.05. 
REsuLts
HH PatHWaY CoMPonEnts ExPREssIon In
HEPatobLastoMa tIssuEs
to investigate if Hh pathway were changed with hu-
man hepatoblastoma development and metastasis, Hh
pathway components expression analyses were carried
out by immunohistochemistry. fig. 1 shows the repre-
sentative profile of immunostaining for shh, Patched,
smo and gli1 in both the cytoplasm and nuclei. shh
expression was heterogenous and localized to the cy-
toplasm, stroma and glandular lumen of tumor. Ptc
and smo were localized to the cytoplasm of neoplastic
epithelium and cell membrane, and a heterogeneous
expression pattern of gli1 in the cancer group was
observed. gli-1 was mainly localized to the cytoplasm
and scattered nucleus of hepatoblastoma tumor cells.
shh protein expression was present in almost all tu-
mors at different levels and had highest expression in
cancer groups. the results from immunohistochemical
analysis  of  Hh  pathway  components  with  regard  to
the malignant potential of hepatoblastoma are sum-
marized in table 1. Elevated expression of shh was
observed in 87.5% (28/32) of hepatoblastoma, where-
as its expression was weak or undetectable in cholesta-
sis (P = 0.040, Chi-square) and normal tissues (P =
0.008, Pearson’s c2 test). Patched and smo expression
were  also  intensively  expressed  in  hepatoblastoma,
they were observed very weakly in any cholestasis and
normal tissues. no significant difference in their pro-
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2 Guo_Umbruchvorlage  11.11.10  17:29  Seite 469tein expressions was found between hepatoblastoma
and cholestasis tissues (P = 0.143, Pearson’s c2 test).
the expression of gli1 protein in the cytoplasm also
increased in tumor tissues compared with that in the
cholestasis and normal liver tissues (table 1, Pearson’s
c2 test).  there  was  significant  correlation  between
gli1 and Patched or smo expression. there was also a
positive correlation between Patched expression and
smo expression in hepatoblastoma (Data not shown). 
CLInICoPatHoLogIC fEatuREs of gli-1 staInIng
the clinicopathologic features of the 32 hepatoblas-
toma cases with theirs Hh pathway components stain-
ing data are summarized in table 2. of the 32 hepato-
blastoma  patients,  gli-1  overexpression  correlated
with different histological type (P = 0.046), tumor size
(P = 0.030) and clinical stage (P = 0.000) respectively,
whereas  smo  overexpression  correlated  with  clinical
stage  (P  =  0.010),  Preoperative  chemotherapy  (P  =
0.022) and prognosis (P = 0.022). the levels of smo
and  gli-1  in  tumours  obtained  after  preoperative
chemotherapy did significantly differ from those in tu-
mours obtained without any therapies. the levels of
smo  and  gli-1  significantly  increased  in  advanced
stages (stages IIIa, IIIb, and IV, P=0.010 and 0.000,
respectively). there was no significant correlation be-
tween the levels of serum afP and gli-1 (Data not
shown). there were no significant associations of gli-
1 staining with gender, age (P > 0. 05 for all of the
analyses).
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Table 1. Hh pathway components staining status in hepato-
blastoma, cholestasis tissues and control.
Variables hepato- cholestasis  Control
blastoma tissues
PP
(n = 32) (n = 12) (n = 8)
shh
(+) 28 7 0.040 3 0.008
(-) 45 5
gli-1
(+) 22 6 0.143 2 0.032
(-) 10 66
smo
(+) 21 7 0.245 2 0.041
(-) 11 56
Ptc
(+) 26 8 0.181 4 0.075
(-) 64 4
Fig. 1. a representative series of immunohistochemical staining of Hh signaling components from hepatoblastoma patients. (a)
Immunohistochemistry for CK-7 expression (expected deeply-brown) in liver sections from a child with ba demonstrating the
expression of shh was present in the cytoplasm of epithelium and stroma tissues. (b) Patched and (C) smo expression was ob-
served in cytoplasm and cell membrane of tumors. (D) gli1 expression was scattered found in nuclear of hepatoblastoma cells.
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to evaluate the prognostic value of smo and gli1, we
then  carried  out  Cox  regression  analyses,  we  per-
formed a log-rank test followed with Kaplan-Meier es-
timates. the overall Kaplan-Meier survival curves for
smo and gli1 staining expression are shown in fig. 2.
the  overall  Kaplan-Meier  survival  curves  of  all  pa-
tients (fig. 2a) show that the 5-year survival rate in
the  patients  with  gli1  pisitive  expression  was  53%,
while that in the remaining patients was approximately
72%. the prognosis of the patients with positive ex-
pression of gli1 was significantly worse than that of
other patients. similarly, patients with positive expres-
sion of smo (n = 21) also had poorer survival than
those with negative smo expression (n = 11). since the
levels  of  gli1  were  significantly  correlated  with  ad-
vanced stages of tumour, the correlation between gli1
expression and prognosis was examined in tumours in
early  stages  (stage  I  or  II),  and  those  in  advanced
stages (stage III or IV), separately. the prognosis of
the  21  advanced  stages  patients  with  high  levels  of
gli1 expression was significantly poor in advanced tu-
mours.  among  them  12  patients  with  gli-1  nuclear
(ﾱ)  expressing  cancers  died  from  distant  metastasis
within  a  few  months.  three  (16.7%)  of  the  24  ad-
vanced  cases  with  low  gli-1  expression  remain  dis-
ease-free. In 8 patients with early tumours, all 7 pa-
tients with low levels of gli1 expression are alive dis-
ease free and one out of eight patients with high levels
of  gli1  expression  showed  poor  prognosis.  one  of
the 8 cases with early stage hepatoblastoma showed
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Table 2. association between shh, gli1 and gli-1 staining and pathological characteristics of hepatoblastoma patients (Pear-
son’s c2 test).
Prognostic factors shh(+) smo(+) gli-1(+)
PP P
n(%) n(%) n(%)
age(y)(n) 
0-2 years( 15) 13 0.554 10 0.508 10 0.571
2-5 years ( 12) 11 89
over 5 years (5) 433
gender
female (10) 9 0.704 5 0.148 7 0.625
Male (21) 19 16 15
Histology
Well (17) 13 0.07  9 0.108 9 0.046
Poorly (15) 15 12 13
tumor size
n ≤ 2 (3) 2 0.056 1 0.070 1 0.030
2 < n ≤ 5 (14) 11 88
5 < n (15) 15 12 13
stage
stages I, II (8) 5 0.078 2 0.010 1 0.000
stagesIII, IV (24) 23 19 21
Preoperative chemotherapy
Yes(17) 14 0.350 8 0.022 9 0.046
no (15) 14 13 13
Prognosis
survived with evidence-free (19) 15 0.108 8 0.022 10 0.020
Recurrence/died of disease (13) 13 13 12
Fig. 2. Kaplan-Meier curves for
overall  survival  of  the  patient
population with hepatoblastoma.
a, overall survival according to
gli1 status. patients with nuclear
gli1 (+) showed poorer survival
rates than those with tumors ex-
pressing gli1 (-) (P < 0.01, log-
rank test). b, survival according
to the levels of smo expression.
Patients  with  smo  (+)  pattern
showed  poorer  outcome  than
the remainder of the population
(P < 0.01). 
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of shh. these results indicate that a significant inverse
relationship of gli1 expression with a poor prognosis
was observed during a 5-year follow-up and suggest
that gli1 expression is a valuable biomarker of prog-
nosis.
MuLtIVaRIatE anaLYsIs of gli1 ExPREssIon
to identify which independent factors had a signifi-
cant  influence  on  survival,  multivariate  analysis  of
overall  survival  using  the  Cox  proportional  hazards
model was further performed to determine the prog-
nostic value of smo and gli1 expression when adjust-
ed with other prognostic factors. for this multivariate
analysis, variables with P-value lower than 0.30 in the
univariate analysis were also selected: tumor grade, his-
tologic type, curative surgery, preoperative chemother-
apy and stage classification. as stage classification was
significantly  associated  with  distant  metastasis,  we
used  stage  classification  in  this  multivariate  analysis.
Cox’s  regression  analysis  showed  that  gli1  was  an 
independent  prognostic  factor  adjusted  by  tumor
grade, stage, histologic type and patients’ age (table 3, 
P < 0.01). survival curves were also confirmed this re-
sults. for preoperative chemotherapy, the difference in
tumor survival lost statistical significance in the multi-
variate analysis. 
DIsCussIon
uptonow, there is no report concerning prognosis im-
plications of Hh signaling pathway with hepatoblas-
toma. our data revealed that Hh pathway components
are active in hepatoblastoma patients, which is in ac-
cordance with previous data about a variety of human
cancers [14, 15]. In the current study, besides confirm-
ing  the  increased  expression  of  shh,  Patched,  smo
and gli1 proteins in hepatoblastoma compared with
cholestasis liver tissue, we also found for the first time,
that hepatoblastoma patients who were high expres-
sion  for  Hh  pathway  components  showed  poorer
prognosis than those who were low expression for Hh
pathway components. this appears to be the first at-
tempt to link Hh pathway components with outcome
of hepatoblastoma patients, in particular, gli1 was in-
dependent of other clinicopathological parameters.  
Hh signaling pathway controls many aspects of cell
differentiation, tissue patterning and embryonic devel-
opment [16]. In normal tissues, Hh-induced progeni-
tor-cell proliferation is transient and tightly regulated,
resulting in acute epithelial repair and regeneration af-
ter injury. In contrast, aberrant activation of tumour
Hh signalling cascades is not controlled by regulatory
mechanisms,  leading  to  support  survival  of  tumour
clonogens  and  tumour  regrowth  in  an  auto  crine-
paracrine manner [17, 18]. aberrant activation of the
pathway was reported in a variety of human cancers. It
have  already  been  reported  a  significant  correlation
between high Hh pathway activity and poor outcomes
of patients and such tumours showed a high recur-
rence rate. In childhood tumours, Hh pathway were
detected in a majority of cases of intestinal stromal tu-
mors [19]. However, the role of the Hh pathway in
human hepatoblastoma is still unclear. In the current
study, we investigated the expression of Hh pathway
components including shh, Ptc, smo and gli-1 using
immunohistochemical  techniques.  our  data  demon-
strated that shh and gli-1 were expressed at higher
levels in hepatoblastoma than in cholestasis and nor-
mal liver tissue. the expression of shh correlated with
high risk hepatoblastoma and large tumor sizes. 
the signals that can influence migratory potential
are thought to result in highly aggressive cancer forms
and thereby contribute to cancer recurrence since all
stage  4  cases  underwent  different  chemotherapeutic
regimen,  one  explanation  for  this  result  is  that
chemotherapy might have not been effective in pre-
venting recurrence in these four early cases. Indeed,
postoperative  adjuvant  chemotherapy  failed  to  im-
prove  the  prognosis  of  patients  with  gli-1  nuclear-
positive tumours. any therapeutic intervention could
not arrest the disease progression in association with
Hh signal activation. thus, in early stage tumours, se-
lection of patients for chemotherapy based on high
Hh activity might be an effective method to improve
the prognosis of this category of patient. Moreover,
the exclusion of low-risk patients from postoperative
chemotherapy could spare some of its serious side ef-
fects. these results suggest that Hh signal activation
might promote cancer regrowth and progression after
chemotherapy, and that subtle gli-1 activation is in-
dicative of the emergence of ‘more aggressive’ cancer
cells. Hh activation even after chemotherapy correlat-
ed with earlier relapse and treatment resistance. the
useful biological prognostic factors are of great clini-
cal importance for discriminate a subgroup of hepato-
blastoma with more aggressive biological properties,
which correlate with a poor prognosis. Hh pathway ac-
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Table 3. univariate and Multivariate analysis of potential molecular markers for overall survival of hepatoblastoma.
univariate  P Multivariate HR (95%CI)* P
Preoperative chemotherapy
(yes versus no) 1.36(0.89-3.79) 0.046 2.16(0.91-5.11) 0.074
surgical resection
( yes versus no) 1.81(0.92-3.62) 0.082 2.13(1.17-4.43) 0.033
gli1 expression
(positive versus negative) 4.75(1.16-15.61) 0.011 6.34(1.35-18.86) 0.007
Patched expression
(positive versus negative) 2.53(0.81-5.86) 0.161 3.12(0.93-6.45) 0.084
* adjusted for tumor grade, histologic type, and stage classification 
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tivity may correlate with malignant potential in child-
hood malignant tumour hepatoblastoma. 
to identify high-risk patients with hepatoblastoma,
we also documented a heterogeneous protein expres-
sion pattern of Hh signal components in the cancer
group. our results also suggest that Patched and gli1
protein  overexpression  were  correlated  with  poor
prognosis of patients, which were also suggested in
other cancers [19, 20]. gli-1 nuclear expression might
therefore be a useful and reliable biomarker for the
screening and management of high-risk patients with
poorer  prognosis.  More  importantly,  the  association
between  Patched  and  gli1  protein  overexpression
with  poor  survival  of  hepatoblastoma  patients  was
demonstrated  for  the  first  time.    were  significantly
correlated with the outcome of patients. among the
three  independent  parameters,  gli1  protein  overex-
pression, stage of disease, and histological type, the
risk of gli1 protein overexpression was highest, indi-
cating  that  Hh  signal  activation  is  the  most  useful
prognosis-associating  factor  in  hepatoblastoma.  of
course,  tnM  staging  in  clinical  practice  is  widely
used, and its high prognostic capability is generally ac-
cepted.  tnM  classification  is  based  on  the  clinico-
pathologic characteristics, and lack of biological and
molecular  information,  such  as  marks  of  prolifera-
tion,  angiogenesis,  invasiveness,  apoptosis.  thus,  it
cannot predict perfectly the outcome for a particular
individual.  using  gli-1  as  prognostic  factors  may
compensate  for  the  shortage  of  tnM  system,  as
proven by success of molecular and gene marks in he-
patoblastoma  for  prognosis.  furthermore,  analysis
can be performed by biopsy even with blood samples
from patients. In spite of its variability, it is easily ac-
cessible, so it may be helpful for diagnosis and pre-
dicting  early-stage  cancer  in  patients  before  radical
surgery or in patients who cannot undergo surgery. It
was reported that Hh signaling pathway was related to
the  cancer  cell  mobility,  migration  and  invasiveness
[21], probably through directly participating in cell mi-
gration  and  angiogenesis  processes  [22].  the  func-
tional  properties  of  such  cells  might  be  influenced
through cell proliferation, migration, invasion and an-
giogenesis-promoting effect and apoptosis-inhibiting
effect of gli1 overexpression [23]. 
In  conclusion,  molecular  evaluation  of  Hh  signal
components have shown that overexpression of gli1
and Patched correlated with poor clinical outcome in
hepatoblastoma. It is tempting to speculate that Hh
pathway may be useful in the evaluation of hepato-
blastoma as a decision-making biomarker for predict-
ing treatment efficacy. Prospective studies in a larger
population including very early-stage patients should
be  carried  out.  although  the  functional  and  clinical
significance of the Hh pathway remains to be elucidat-
ed, we suggest that gli-1 expression is a potential di-
agnostic biomarker and therapeutic target. We also an-
ticipate that the Hh signal pathway will continue to be
a significant target in investigation of cancer therapies.
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